Related Experiment Video
Updated: Nov 23, 2025

09:39
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
7.1K
Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan
Declan M Gorman1, John Lee1, Colton D Payne1
1School of Biomedical Sciences, The University of Queensland, Brisbane, Australia.
Amino Acids
|January 5, 2021
Abstract:
The complement component C5 inhibitory peptide zilucoplan is currently in phase III clinical trials for myasthenia gravis (MG). Despite being at an advanced stage of clinical development, there have been no published reports in the literature detailing its chemical synthesis. In this work, we describe an approach for the chemical synthesis of zilucoplan and validate that the synthesised compound blocks LPS-induced C5a production from human blood.

